Ligand id: 9334

Name: tigatuzumab

Compound class Antibody
International Nonproprietary Names
INN number INN
8979 tigatuzumab
CS-1008 | humanized LM1 TRA-8
Tigatuzumab (CS-1008) is an investigational, humanized agonistic monoclonal antibody directed against human death receptor 5 (TNFRSF10B; a TNF family catalytic receptor for TRAIL), which is expressed on the surface of many types of cancer cells. DR5 contains an intracellular death domain and interacts with FADD (Fas-associated protein with death domain) to mediate apoptisis.
Peptide sequences and structural information for this antibody are available from its IMGT/mAb-DB record. Peptide sequences matching the heavy and light chain variable regions of tigatuzumab are claimed in patent WO2001083560 [1], but this does not provide an affinity value for the antibody vs. DR5. The antibodies described in the patent were tetsed for their ability to induce apoptosis in cells expressing DR5.
Database Links
Specialist databases
IMGT/mAb-DB 234
Other databases
GtoPdb PubChem SID 318164853
Search PubMed clinical trials tigatuzumab
Search PubMed titles tigatuzumab
Search PubMed titles/abstracts tigatuzumab